Overview

The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

Status:
ENROLLING_BY_INVITATION

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to develop and clinically evaluate 89Zr-labeled HER2-targeted antibodies in diagnosis and screening of HER2-positive cancer patients.

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

Affiliated Hospital of Jiangnan University

Treatments:

Fluorodeoxyglucose F18